Zacks Research Has Pessimistic Outlook of CORT Q3 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research decreased their Q3 2026 earnings estimates for Corcept Therapeutics in a research report issued to clients and investors on Tuesday, March 17th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $0.21 for the quarter, down from their previous estimate of $0.30. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ FY2028 earnings at $3.02 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). The business had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.26 EPS.

CORT has been the subject of several other research reports. UBS Group assumed coverage on Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target for the company. HC Wainwright cut their price objective on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Truist Financial set a $50.00 target price on Corcept Therapeutics in a report on Wednesday, December 31st. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price for the company. in a research report on Wednesday, December 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $77.17.

Corcept Therapeutics Stock Down 0.6%

Shares of NASDAQ:CORT opened at $33.30 on Thursday. The firm has a market cap of $3.54 billion, a P/E ratio of 40.61 and a beta of 0.29. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $117.33. The business has a fifty day simple moving average of $37.57 and a 200 day simple moving average of $62.37. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01.

Insider Buying and Selling at Corcept Therapeutics

In other news, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total value of $817,400.00. Following the completion of the transaction, the insider directly owned 1,235 shares of the company’s stock, valued at approximately $50,474.45. This trade represents a 94.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 48,233 shares of company stock valued at $1,817,306. Company insiders own 20.80% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CORT. Abacus FCF Advisors LLC bought a new position in shares of Corcept Therapeutics during the 3rd quarter worth approximately $3,238,000. Pacer Advisors Inc. increased its stake in shares of Corcept Therapeutics by 6,796.7% in the 3rd quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock valued at $32,459,000 after acquiring an additional 384,896 shares in the last quarter. Brown Capital Management LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at $19,950,000. Cerity Partners LLC lifted its position in shares of Corcept Therapeutics by 21.4% during the 2nd quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company’s stock valued at $54,800,000 after acquiring an additional 131,799 shares during the period. Finally, Synergy Asset Management LLC lifted its position in shares of Corcept Therapeutics by 96.1% during the 3rd quarter. Synergy Asset Management LLC now owns 506,856 shares of the biotechnology company’s stock valued at $39,615,000 after acquiring an additional 248,362 shares during the period. Institutional investors own 93.61% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Lead‑plaintiff deadline: multiple firms remind investors that April 21, 2026 is the deadline to move for lead plaintiff in the pending securities class action — an immediate procedural date that could determine litigation leadership and the pace of the case. Robbins LLP Notice
• Negative Sentiment: Allegations of disclosure failures and regulatory/patent setbacks: Hagens Berman and others say the lawsuit stems from an alleged concealment of repeated FDA warnings about insufficient data and a federal court patent loss — claims that, if proven, could drive material damage awards or settlements and prolonged expense. Hagens Berman Alert
• Negative Sentiment: Multiple law firms soliciting clients: At least a dozen plaintiff firms (Robbins, Levi & Korsinsky, Rosen, Pomerantz, Kahn Swick & Foti, Glancy, Bronstein, Schall, Bernstein, Gross, et al.) have issued investor alerts and filings covering the Oct. 31, 2024–Dec. 30, 2025 class period — increasing the likelihood of a contested, high‑profile suit and amplification of reputational and financial risk. Kahn Swick & Foti / GlobeNewswire

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.